SIGLEC10 and neoplasm: The fold‐change of Siglec‐10 downmodulation between normal and tumor cells was on average higher among CLL cases with unfavorable prognosis (uCLL vs. mCLL) (Appendix Fig S5A), however, did not reach statistical significance.